Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 1;106(12):3215-3218.
doi: 10.3324/haematol.2021.278779.

Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status

David Baker  1 , Milan Bimali  2 , Luis Carrillo  3 , Archana Sachedina  4 , Daisy Alapat  3 , Md Shadiqul Hoque  1 , Mathew Kottarathara  1 , Richa Parikh  1 , Amani Erra  1 , Angel A Mitma  1 , Pankaj Mathur  1 , Yetunde Ogunsesan  1 , Lakshmi Yarlagadda  1 , Sravani Gundarlapalli  1 , Sharmilan Thanendrarajan  1 , Maurizio Zangari  1 , Frits Van Rhee  1 , Guido Tricot  1 , Carolina Schinke  5
Affiliations

Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status

David Baker et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Reassessment of traditional risk factors in first multiple myeloma relapse shows improved prognostic accuracy compared to their evaluation at diagnosis (shown in the Online Supplementary Appendix). GEP70 high-risk (HR) patients at relapse had significant worse progression-free survival (PFS) (A), and OS (B) compared to low-risk (LR) patients, P<0.01. HR fluorescence in situ hybridization (FISH) included translocation t14;16, t4;14 and del 17p and showed worse PFS (P=0.1) (C) and OS (P<0.05) (D), compared to patients with LR FISH. Assessment of revised International Staging System (RISS) at relapse showed significant worse PFS, E, and OS, F, for patients with RISS 2+3 compared to patients with RISS stage I. The presence of >3 focal lesions by positron emission tomography and computed tomography (PET CT) at relapse was associated with worse PFS (H) and OS (I) in first relapse. The results were not significant, likely due to the relative small patient number. Achievement of minimal residual disease (MRD) negativity after first relapse was a powerful marker for significantly improved PFS (J) and OS (K).
See this image and copyright information in PMC

References

    1. Kristinsson SY, Anderson WF, Landgren O. Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia. 2014; 28(6):1346-1348. - PubMed
    1. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014; 28(5):1122-1128. - PMC - PubMed
    1. Schinke M, Ihorst G, Duyster J, Wasch R, Schumacher M, Engelhardt M. Risk of disease recurrence and survival in patients with multiple myeloma: a German Study Group analysis using a conditional survival approach with long-term follow-up of 815 patients. Cancer. 2020; 126(15):3504-3515. - PubMed
    1. Fonseca R, Monge J, Dimopoulos MA. Staging and prognostication of multiple myeloma. Expert Rev Hematol. 2014;7(1):21-31. - PMC - PubMed
    1. Hillengass J, Usmani S, Rajkumar SV, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20(6):e302-e312. - PubMed

Publication types

MeSH terms

Substances